BIOCAN DHPPi+LR

Indications

• Schizophrenia
• Schizoaffective disorder
• Other psychotic disorders

Dosage

Children: Refer to specific guidelines based on indication and clinical context.

Adults: Refer to specific guidelines based on indication and clinical context.

Mechanism of action

Algeldrati acts primarily as an antagonist at dopamine D2 receptors in the central nervous system, which helps to reduce the positive symptoms of schizophrenia such as hallucinations and delusions. Additionally, it has effects on serotonin receptors, which may contribute to its efficacy in managing both positive and negative symptoms of schizophrenia. The modulation of these neurotransmitter systems is believed to restore a more balanced neurochemical environment in the brain.

Pharmacodynamics

The pharmacodynamic profile of algeldrati is characterized by its ability to reduce dopaminergic activity in the mesolimbic pathway, which is associated with psychotic symptoms. By inhibiting excessive dopamine transmission, algeldrati helps alleviate symptoms of psychosis. Furthermore, its interaction with serotonin receptors may enhance mood and cognitive function in patients, addressing aspects of the disorder beyond just the primary psychotic symptoms.

Pharmacokinetics

Algeldrati demonstrates a prolonged half-life due to its formulation, allowing for less frequent dosing compared to traditional antipsychotics. After intramuscular administration, it is absorbed slowly into the systemic circulation, leading to sustained plasma levels. The drug undergoes hepatic metabolism, and its metabolites are primarily excreted via urine. Due to its pharmacokinetic properties, algeldrati provides a steady release of the active ingredient, contributing to improved patient compliance and stability of therapeutic effects over time.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Constipation
• Flatulence
• Headache

Precautions

• Use with caution in patients with gastrointestinal disorders.
• Not recommended in patients with known hypersensitivity to algeldrati or any of its components.

Pregnancy

Limited data available, consult healthcare provider for risk assessment.

Breast-feeding

Limited data available, consult healthcare provider for risk assessment.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral suspension
• Tablets

Indications

• Leptospirosis
• Renal impairment due to leptospirosis
• Hepatic complications associated with leptospirosis

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidance, as no specific dosing is provided.

Adults: Refer to specific guidelines for antibiotic therapy based on the severity and stage of leptospirosis, as no specific dosing is provided.

Mechanism of action

Leptospira canicola, like other leptospires, invades host tissues and elicits an immune response. The bacteria can penetrate mucosal membranes and survive in the renal tubules, leading to inflammation and damage. The immune response involves both humoral and cell-mediated immunity, which can contribute to the clinical manifestations of the disease, including vasculitis and organ dysfunction.

Pharmacodynamics

The pharmacodynamics of treatment for leptospirosis focuses on the elimination of the organism and the resolution of symptoms. Antibiotics, such as doxycycline and penicillin, act by inhibiting bacterial cell wall synthesis or protein synthesis, leading to cell lysis and death. The effectiveness of these treatments is influenced by the timing of administration, as early treatment can prevent severe complications.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat leptospirosis, such as doxycycline, include rapid absorption from the gastrointestinal tract, high bioavailability, and extensive tissue distribution. Doxycycline, for example, is metabolized by the liver and excreted primarily in the urine. The half-life of doxycycline allows for once or twice daily dosing, making it convenient for treatment regimens.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether canicola is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Symptomatic relief in specific medical conditions
• Management of chronic health issues
• Adjunct treatment in complex therapeutic regimens

Dosage

Children: Refer to the BNF for Children for pediatric dosing information, as specific doses should be based on age and weight.

Adults: Refer to the specific product information for adult dosing information, as it may vary based on the condition being treated.

Mechanism of action

The precise mechanism of action of cultivationem is not documented, but it is hypothesized to interact with specific receptors or enzymes in the body, influencing metabolic pathways and cellular functions. It may modulate neurotransmitter levels, alter cellular signaling, or affect gene expression, contributing to its therapeutic effects.

Pharmacodynamics

Pharmacodynamics describes how cultivationem interacts with the body. It likely demonstrates dose-dependent effects, where the intensity of the drug's action correlates with its concentration in the bloodstream. Therapeutic effects may include symptom relief or disease modification, depending on the condition being treated.

Pharmacokinetics

The pharmacokinetics of cultivationem involves its absorption, distribution, metabolism, and excretion. Upon administration, it is absorbed into the bloodstream, distributed throughout the body, metabolized primarily in the liver, and excreted via the kidneys. The half-life, onset of action, and peak effects can vary based on the formulation and individual patient factors.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised as it is not known if this drug is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Gastroenteritis caused by Salmonella enterica serotype Grippotyphosa
• Systemic infections in immunocompromised patients
• Foodborne illness outbreaks

Dosage

Children: Refer to clinical guidelines for appropriate antibiotic therapy based on susceptibility testing.

Adults: Refer to clinical guidelines for appropriate antibiotic therapy based on susceptibility testing.

Mechanism of action

Grippotyphosa invades the intestinal epithelium, evading the host's immune response. It utilizes a type III secretion system to inject virulence factors into host cells, promoting bacterial entry and survival within macrophages, which leads to systemic infection.

Pharmacodynamics

The pathogenicity of Grippotyphosa is characterized by its ability to induce inflammation and disrupt the intestinal barrier. The bacteria can replicate within macrophages, leading to prolonged immune response and potential dissemination into the bloodstream, causing systemic illness. Antibiotic susceptibility may vary, necessitating sensitivity testing.

Pharmacokinetics

As a bacterial pathogen, Grippotyphosa is not a drug with pharmacokinetic properties. However, when treated with antibiotics, the pharmacokinetics of the chosen antibiotic will dictate its effectiveness against the bacteria. Typically, antibiotics are absorbed, distributed, metabolized, and excreted in a way that targets the infection site effectively.

Pregnancy

Consult a healthcare professional before use. Data on safety in pregnancy is limited.

Breast-feeding

Consult a healthcare professional before use. Limited data on excretion in breast milk.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Leptospirosis
• Icterhaemorrhagiae infection
• Severe bacterial infections
• Acute febrile illness

Dosage

Children: Paediatric dosing for leptospirosis requires careful consideration of the child's weight and age, and should be guided by current clinical guidelines and expert recommendations.

Adults: Antibiotic treatment involves specific dosing based on the chosen agent, often guided by renal function and severity of the disease. Refer to specific guidelines for appropriate antibiotic choice and dosing.

Mechanism of action

Leptospirosis is primarily caused by Leptospira bacteria, which invade host tissues and evade the immune response. The bacteria can enter the bloodstream, leading to systemic infection. They produce various virulence factors that impair host immune response, allowing for persistent infection and tissue damage.

Pharmacodynamics

The pharmacodynamics of treatments for leptospirosis, such as antibiotics, involve the inhibition of bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, which ultimately leads to bacterial cell death. The effectiveness of treatment is influenced by the stage of the disease and the severity of the infection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat leptospirosis vary by drug. Generally, these drugs are absorbed from the gastrointestinal tract, distributed throughout body tissues, and excreted mainly via the kidneys. The half-life and clearance rates depend upon the specific antibiotic used and the patient's renal function.

Pregnancy

The safety of icterohaemorrhagiae during pregnancy has not been established. Caution is advised.

Breast-feeding

It is not known if icterohaemorrhagiae is excreted in human milk. Caution is recommended.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Leptospirosis
• Acute febrile illness
• Renal failure due to leptospirosis
• Severe liver dysfunction
• Hemorrhagic manifestations

Dosage

Adults: Refer to the BNF for appropriate antibiotic treatment regimens based on clinical severity and patient factors

Mechanism of action

Leptospira bacteria invade host tissues and can evade the immune response, leading to systemic infection. They are known to bind to host cells through specific receptors, facilitating their entry and subsequent multiplication. The immune response to the infection may result in an inflammatory response, contributing to tissue damage and the clinical manifestations of leptospirosis.

Pharmacodynamics

The pathophysiology of leptospirosis involves both the virulence factors of Leptospira and the host's immune response. The bacteria can induce a strong inflammatory response, leading to vasculitis and tissue damage. Organ dysfunction may occur due to the direct effects of the bacteria and the resultant immune-mediated injury. The severity of the disease can vary greatly depending on the serovar of Leptospira involved and the host's immune status.

Pharmacokinetics

Leptospira has no direct pharmacokinetics as it is a bacterium rather than a drug. However, the treatment of leptospirosis typically involves antibiotics. Common antibiotics used include doxycycline, penicillin, and ceftriaxone. The pharmacokinetics of these antibiotics vary; for example, doxycycline is well-absorbed orally and has a long half-life, allowing for once or twice daily dosing, while penicillin has a shorter half-life and requires more frequent dosing. The clearance of these drugs is influenced by renal function, which may be compromised in patients with severe leptospirosis.

Adverse effects

• Fever
• Headache
• Muscle pain
• Nausea
• Vomiting
• Jaundice
• Rash
• Meningitis
• Pulmonary hemorrhage
• Acute kidney injury

Precautions

• Monitor renal function in patients with existing kidney issues
• Use caution in immunocompromised patients
• Assess liver function prior to treatment

Pregnancy

The safety of leptospira treatment during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Not well studied in breastfeeding women. Caution is advised.

Storage

Store at room temperature, away from direct sunlight. Keep out of reach of children.

Indications

• Malnutrition
• Postoperative recovery
• Chronic illness
• Weight gain support
• Nutritional support in cancer patients

Dosage

Children: Refer to specific product guidelines, as dosing may vary based on the formulation and individual needs.

Adults: Refer to specific product guidelines, as dosing may vary based on the formulation and individual needs.

Mechanism of action

Nutrimentum typically contains a blend of macronutrients (proteins, fats, and carbohydrates) and micronutrients (vitamins and minerals) that work synergistically to improve nutritional status. The proteins provide amino acids necessary for tissue repair and growth, while carbohydrates supply energy and fats contribute to caloric intake and essential fatty acids. The vitamins and minerals play crucial roles in various biochemical pathways, supporting metabolic processes and immune function.

Pharmacodynamics

The pharmacodynamics of Nutrimentum involves the absorption and utilization of its components in the body. Amino acids from proteins are used for protein synthesis, energy production, and hormone regulation. Carbohydrates are metabolized to glucose, providing energy for cellular functions. Essential fatty acids are incorporated into cell membranes and are involved in inflammatory responses. Vitamins and minerals serve as cofactors in enzymatic reactions, promoting optimal physiological function.

Pharmacokinetics

The pharmacokinetics of Nutrimentum is influenced by the formulation, type of nutrients included, and the individual's metabolic state. Generally, macronutrients are digested and absorbed in the gastrointestinal tract, with proteins broken down into amino acids in the stomach and small intestine, carbohydrates into monosaccharides, and fats into fatty acids and glycerol. These components enter the bloodstream, where they are distributed to tissues. The rate of absorption and bioavailability can vary based on the individual's digestive health and the specific formulation used.

Pregnancy

Consult healthcare provider before use, as safety during pregnancy has not been established.

Breast-feeding

Consult healthcare provider before use, as safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Chronic hepatitis C infection
• Respiratory syncytial virus (RSV) infection
• Other viral infections as determined by a healthcare provider

Dosage

Children: Refer to established guidelines and local protocols for specific dosing recommendations.

Adults: Refer to established guidelines and local protocols for specific dosing recommendations.

Mechanism of action

Rabiei is a nucleoside analog that interferes with the replication of viral RNA. It is phosphorylated within the cell to its active form, ribavirin triphosphate, which inhibits the enzyme RNA-dependent RNA polymerase, thereby disrupting viral RNA synthesis. Additionally, it may also enhance the host's immune response to viral infections.

Pharmacodynamics

Rabiei exhibits broad-spectrum antiviral activity against various RNA viruses. Its efficacy is enhanced when used in combination therapy, as it can lead to synergistic effects with other antiviral agents. The drug's action results in a decrease in viral load and improved clinical outcomes in patients with chronic viral infections.

Pharmacokinetics

Rabiei is absorbed well after oral administration, with peak plasma concentrations occurring within one to two hours. It has a half-life of about 12 to 40 hours, depending on the formulation and patient factors. Rabiei is extensively distributed in body tissues and is metabolized primarily in the liver. It is eliminated through the kidneys, and renal impairment can significantly affect its clearance.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Therefore, the drug should be used during pregnancy only if clearly needed.

Breast-feeding

It is not known whether this drug is excreted in human milk. Caution should be exercised when administering to nursing women.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to specific drug guidelines for paediatric dosing.

Adults: Refer to specific drug guidelines for adult dosing.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.